Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plan B Pioneers OTC “Pharmacy Counter” Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Behind-the-counter, dual status approval breaks the hold on commissioner nominee von Eschenbach.

You may also be interested in...



Von Eschenbach Promotes Behind-The-Counter Drug Class

FDA commissioner says creation of a third regulated therapeutic class would apply to drug, biologic and device products.

Von Eschenbach Promotes Behind-The-Counter Drug Class

FDA commissioner says creation of a third regulated therapeutic class would apply to drug, biologic and device products.

White House Faces Subpoena On Plan B Communications With FDA

Suit broadened after court finds FDA acted in “bad faith.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel